All In Biotech

Drug Trial Radar · NCT07220408

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis

A Single Center, Randomized, Double-masked, Vehicle Controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Seasonal Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model

Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 23, 2025

Primary completion

Feb 2026

Study completion Feb 2026

Sponsor

Lead sponsor
Telios Pharma, Inc.Industry
Sponsor type
Industry
First posted
Oct 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 60 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

  • TL-925Drug

    TL-925 is an eye drop.

  • PlaceboDrug

    The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular ItchingTime frame: 3, 5 and 7 minutes after CAC
  2. Conjunctival RednessTime frame: 7, 15 and 20 minutes after CAC

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Advancing Vision Research

    Smyrna, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.